SCHEMBL6729567

SCHEMBL6729567

CS(=O)(=O)c1ccc(-c2c(-c3cccc(C(F)(F)F)c3)noc2C(F)F)cc1F

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.42
ELANE P08246 2/20 0.41
PTGS2 P35354 3/20 0.40
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ALOX5AP P20292 2/20 0.37
FEN1 P39748 2/20 0.37
MAPT P10636 2/20 0.37
GAA P10253 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
MCOLN3 Q8TDD5 1/20 0.37
POLB P06746 1/20 0.36
NR1H2 P55055 2/20 0.36
NR1H3 Q13133 2/20 0.36
GPBAR1 Q8TDU6 1/20 0.36
IKBKB O14920 1/20 0.35
NR1H4 Q96RI1 1/20 0.35
AKR1C3 P42330 1/20 0.35
AKR1C2 P52895 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7115446 0.90 BRD4 (0.40) BRD4ELANEPTGS2MAPTGAA
SCHEMBL6723024 0.90 BRD4 (0.42) BRD4PTGS2ALOX5APFEN1MAPT
SCHEMBL6726764 0.90 PTGS2 (0.42) PTGS2MEN1KMT2AALOX5APFEN1
SCHEMBL6726701 0.88 PTGS2 (0.38) PTGS2
SCHEMBL6730308 0.87 PTGS2 (0.37) ELANEPTGS2MEN1KMT2AGAA
SCHEMBL6722905 0.87 PTGS2 (0.46) BRD4ELANEPTGS2MEN1KMT2A
SCHEMBL6721754 0.87 PTGS2 (0.55) BRD4ELANEPTGS2MEN1KMT2A
SCHEMBL6723710 0.86 PTGS2 (0.45) PTGS2
SCHEMBL6719286 0.86 PTGS2 (0.34) ELANEPTGS2MEN1KMT2AIKBKB
SCHEMBL6719025 0.86 PTGS2 (0.43) BRD4PTGS2KMT2APOLBNR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-05-13 US disclosed
EP-1296971-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2003-04-02 EP disclosed
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2002-12-05 US disclosed
WO-2001081332-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, FPR1, PTGES2 BRD4 384/4885ELANE 231/4885PTGS2 5/4885
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, PTGES2, FPR1 BRD4 340/4885ELANE 219/4885PTGS2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.